Analysis of current status of antithrombotic therapy in 136 patients with nonvalvular atrial fibrillation / 中国基层医药

Objective:To analyze the current status and effectiveness of different antithrombotic regimens in patients with non-valvular atrial fibrillation.Methods:The clinical data of 136 patients with non-valvular atrial fibrillation who received treatment in The Second People's Hospital of Yongkang from May 2018 to May 2019 were retrospectively analyzed. According to the treatment plan, they were divided into no antithrombosis group ( n = 32), rivaroxaban group ( n = 41), warfarin group ( n = 42), and aspirin group ( n = 21). Based on treatment of primary disease and complications, patients in the no antithrombosis group were not given anticoagulation or antiplatelet therapy, those in the rivarxaban group were given rivarxaban (10 mg/d), those in the warfarin group were given warfarin (2.5 mg/d), and those in the aspirin group were given aspirin (0.1 g/d). The incidence of thromboembolism and bleeding, all-cause mortality and readmission rate within 1 year were compared among groups. Results:There were significant differences in age, type of atrial fibrillation, coronary heart disease, heart failure, and hypertension among groups (all P < 0.05). There were no significant differences in sex, history of stroke/transient ischemic attack, and the percentage of patients developing diabetes mellitus and hyperlipidemia among groups (all P > 0.05). The incidence of thromboembolic events within 1 year in the no antithrombosis, rivaroxaban, warfarin, and aspirin groups were 21.87% (7/32), 7.32% (3/41), 2.38% (1/42), and 19.05% (4/21), respectively, and there were significant differences among groups ( χ2 = 8.98, P < 0.05). The 1-year incidence of bleeding events in the no antithrombosis, rivaroxaban, warfarin, and aspirin groups were 18.75% (6/32), 29.27% (12/41), 4.76% (2/42), 4.76% (61/21), respectively, and there were significant differences among groups ( χ2 =11.77, P < 0.05). There were no significant differences in the 1-year incidence of thromboembolism events and bleeding events among patients aged < 65 years, 65-75 years, and > 75 years (all P > 0.05), but there were significant difference in all-cause mortality and readmission rate ( χ2 = 6.76, 7.56, both P < 0.05). Conclusion:Early antithrombotic therapy is very important for patients with non valvular atrial fibrillation. The treatment regimens should be individualized, and the risk of death increases with age.

Prevalence of inversions in introns 1 and 22 of the factor VIII gene and inhibitors in patients from southern Brazil / Prevalência das inversões nos íntrons 1 e 22 do gene do fator VIII e inibidores em pacientes do sul do Brasil

ABSTRACT Objectives: The development of antibodies (inhibitors) against exogenous factors is the main complication in the treatment of hemophilia. Both genetic and non-genetic factors are related to inhibitor development. Among the genetic factors, the type of mutation that caused the disease is one of the most important. The objectives of the present study were to establish the prevalence of inversions in introns 1 and 22 of the factor VIII gene in patients with severe hemophilia A, correlating these with inhibitor development, and to compare the results with data from the literature. Method: Unrelated severe hemophilia A patients were analyzed for the presence of inversions in intron 1 (n = 77) and intron 22 (n = 39) by polymerase chain reaction (PCR). Detection of the inhibitor was performed by the mixing test and its quantification was performed by the Bethesda method. Results: The prevalence of inversions in introns 1 and 22 was 2.6% and 41%, respectively. No patient with inversions in intron 1 had inhibitors, whereas 26.3% of patients with inversions in intron 22 developed inhibitors. Conclusion: Due to the small number of patients with inversions in intron 1, it was not possible to perform a statistical test for the correlation with risk of inhibitor development. Inversions in intron 22 of the factor VIII gene were not associated with an increased risk of inhibitor development in the analyzed samples (p = 1).

RESUMEN Introducción: El desarrollo de anticuerpos (inhibidores) contra elfactor exógeno es la principal complicación del tratamiento de hemofilias. Tanto factores genéticos como no genéticos están relacionados con la aparición de los inhibidores. Entre los factores genéticos, el tipo de mutación que originó la enfermedad es uno de los más importantes. El objetivo de este estudio fue establecer laprevalencia de las inversiones en los intrones 1 y 22 del gen del factor VIII en pacientes con hemofilia A severa, relacionándola con el desarrollo de inhibidores, así como comparar los resultados encontrados con datos de la literatura en el mundo. Método: Pacientes con hemofilia A severa no emparentados fueron analizados cuanto a la presencia de inversión en el intrón 1 (n = 77) y de la inversión en el intrón 22 (n = 39), usando la técnica de reacción en cadena de lapolimerasa. La detección del inhibidor fue realizada por el estudio de mezclas; su cuantificación, por el método Bethesda. Resultados: La prevalencia de las inversiones en los intrones 1 y 22 fueron 2,6% y 41%, respectivamente. Ningúnpaciente con la inversión en el intrón 1 presentó inhibidores, mientras 26,3% de los pacientes con la inversión en el intrón 22 desarrollaron anticuerpos. Conclusión: El pequeno número de pacientes con inversión en el intrón 1 no permitió la aplicación de la prueba estadística para correlación con el riesgo de desarrollo de inhibidores. La inversión en el intrón 22 del gen del factor VIII no se asoció a un mayor riesgo de desarrollo de inhibidores en la muestra analizada (p = 1).

RESUMO Introdução: O desenvolvimento de anticorpos (inibidores) contra o fator exógeno é a principal complicação do tratamento de hemofilias. Tanto fatores genéticos quanto não genéticos estão relacionados com o surgimento dos inibidores. Entre os fatores genéticos, o tipo de mutação que originou a doença é um dos mais importantes. Os objetivos do presente estudo foram estabelecer a prevalência das inversões nos íntrons 1 e 22 do gene do fator VIII em pacientes com hemofilia A grave, correlacionando-a com o desenvolvimento de inibidores, bem como comparar os resultados encontrados com dados da literatura mundial. Método: Foram analisados pacientes hemofílicos A graves não aparentados quanto à presença da inversão no íntron 1 (n = 77) e da inversão no íntron 22 (n = 39), utilizando a técnica de reação em cadeia dapolimerase (PCR). A detecção do inibidor foi realizada pelo teste de mistura; a sua quantificação, pelo método de Bethesda. Resultados: As prevalências das inversões nos íntrons 1 e 22 foram de 2,6% e 41%, respectivamente. Nenhum paciente com a inversão no íntron 1 apresentou inibidores, enquanto 26,3% dos pacientes com a inversão no íntron 22 desenvolveram os anticorpos. Conclusão: O número reduzido de pacientes com a inversão no íntron 1 não permitiu a aplicação de teste estatístico para a correlação com o risco de desenvolvimento de inibidores. A inversão no íntron 22 do gene do fator VIII não se associou ao maior risco de desenvolvimento de inibidores na amostra analisada (p = 1).

Life-threatening hemorrhage secondary to acquired deficiency of coagulation factors VIII and XI related to systemic lupus erythematosus: case report / Hemorragia severa secundaria a deficiencia adquirida de factores VIII y XI de la coagulación relacionada con lupus eritematoso sistémico: reporte de caso

ABSTRACT In patients with autoimmune diseases, the simultaneous occurrence of lupus anticoagulant and blood coagulation factors inhibitors is infrequent and is associated with hemorrhagic events. In these cases, the initial approach requires a thorough interpretation of coagulation laboratory tests and mixing studies to reach a definitive diagnosis. We report the case of a patient with systemic lupus erythematosus and Sjögren's syndrome who presented with hemorrhagic diathesis caused by circulating inhibitors against factors VIII and XI coexisting with lupus anticoagulant. The inhibitors eradication was made with rituximab, achieving good results.

RESUMEN La ocurrencia simultánea de anticoagulante lúpico e inhibidores circulantes contra los factores de la coagulación es infrecuente en los pacientes con enfermedad autoinmune, y está relacionada con eventos hemorrágicos. El abordaje inicial requiere una adecuada interpretación de los tiempos de coagulación y prueba de mezcla con plasma para alcanzar el diagnóstico definitivo. Se reporta el caso de una paciente con lupus eritematoso sistémico y síndrome de Sjögren, quien se presentó con trastorno hemorrágico amenazante de la vida ocasionado por inhibidores circulantes contra los factores VIII y XI de la coagulación en coexistencia con anticoagulante lúpico. El tratamiento de erradicación de los inhibidores se realizó con rituximab, con buenos resultados.

Expressions of plasma D-dimer, von Willebrand factor antigen and blood coagulation factor Ⅶ in lymphoma and their clinical significances / 白血病·淋巴瘤

Objective@#To investigate the clinical value of blood coagulation and fibrinolysis index detection in lymphoma patients.@*Methods@#A total of 115 lymphoma patients hospitalized at Zhongshan Hospital of Xiamen University from January 2013 to September 2017 were retrospectively analyzed. According to the diagnostic and therapeutic criteria of lymphoma from World Health Organization (2008), these patients were divided into chemotherapy remission group (76 cases) and chemotherapy non-remission group (39 cases). A total of 138 healthy examination subjects at the same period were selected as the control group. Coagulation factor Ⅶ (FⅦ), D-dimer (D-D), von Willebrand factor antigen (vWF: Ag) and serum lactate dehydrogenase (LDH) levels were measured in all subjects. Kruskal-Wallis test was used to compare the differences of blood coagulation and fibrinolysis indicators in patients with different lymphoma staging and stratified treatment outcomes. Correlation test of D-D and LDH and disease staging was performed by using Spearman correlation analysis. The receiver operating characteristics (ROC) curve was used to analyze the efficacy of D-D in the assisted diagnosis of lymphoma with thrombosis.@*Results@#The plasma D-D, vWF: Ag levels and FⅦ activity [the median (interquartile range)] in lymphoma patients were higher than those in healthy controls [1 240 ng/ml (1 610 ng/ml) vs. 250 ng/ml (43 ng/ml), Z = -10.728, P < 0.01; 170 ng/ml (113 ng/ml) vs. 105 ng/ml (28 ng/ml), Z = -6.425, P < 0.01; 120% (26%) vs. 96% (26%), Z = -4.602, P < 0.01]. With the increase of Ann Arbor stage, plasma D-D, vWF: Ag levels and FⅦ activity were also increased gradually (all P < 0.05); plasma D-D, vWF: Ag levels and FⅦ activity in lymphoma with thrombosis group were higher than those in the group without thrombosis (all P < 0.01), D-D and vWF: Ag levels in the chemotherapy remission group were lower than those in the chemotherapy non-remission group (all P < 0.01). Plasma D-D levels were positively correlated with LDH level and Ann Arbor stage (r values were 0.414 and 0.530, respectively, all P < 0.01). When the plasma D-D level was 1 735 ng/ml, the sensitivity of diagnosis of thrombosis in patients with lymphoma was 81.8%, the specificity was 85.7%, the area under the ROC curve was 0.894, and the Youden index was the highest (0.675).@*Conclusions@#Clinically, blood coagulation and fibrinolysis in patients with lymphoma can be evaluated by detecting blood coagulation and fibrinolysis indexes such as plasma D-D. Real-time monitoring of plasma D-D level can determine the thrombosis trend of lymphoma patients, and it may play an important role in evaluating the efficacy and prognosis.

Acquired blood coagulation factor Ⅴ deficiency in a patient with severe burn / 中华烧伤杂志

In March 2017, a severely burned male patient aged 36 years with hypovolemic shock was admitted to our hospital. The patient received large quantities of antibiotics and blood products and repeated skin graft after admission, and then he suffered wound errhysis and throat congestion. The patient was healthy before without family history of bleeding or thrombosis disease. Laboratory tests showed that prothrombin time and activated partial coagulation time were remarkably prolonged, blood coagulation factor Ⅴ activity was extremely low, and the result of qualitative test of coagulation factor inhibitor was positive. Acquired blood coagulation factor Ⅴ deficiency was diagnosed. After application of dexamethasone (5 mg, twice per day) and infusion of fresh frozen plasma, blood coagulation indicators of patients recovered in 4 days, the result of qualitative test of coagulation factor inhibitor was negative, and bleeding symptoms were improved.

Influence of clopidogrel on platelet function and inflammation factor in treatment of severe carotid artery stenosis after stent-assisted angioplasty / 药物评价研究

Objective To investigate the effect of clopidogrel on platelet function and inflammation factor in treatment of severe carotid artery stenosis after stent-assisted angioplasty.Methods Patients (120 cases) with severe carotid artery stenosis after stent-assisted angioplasty were chosen and divided into two groups,the control group were given atorvastatin combined with aspirin,and the observation group were given atorvastatin combined with chlorine.The serum coagulants DD level,FIB level,inflammation factor P-chosen element level and restenosis event incidence of two groups were observed.Results D-double polymer of two groups had no significant difference;After surgery,the D-double polymer and FIB level of two groups were all higher (P ＜ 0.05).After surgery for 24 h,the D-double polymer and FIB level of observation group were higher,after 3 months of surgery,the D-double polymer and FIB level had no significant differences compared with before surgery,which were all in normal level.After 24 h,1 month,3 months of surgery,the D-double polymer and FIB level of observation group were all lower than control group (P ＜ 0.05).Before treatment,the P-chosen selectin of two groups had no significant differences,which were all decreased after surgery,and the observation group was lower than control group (P ＜ 0.05);The restenosis event of observation group was lower than control group (P ＜ 0.05).Conclusion Clopidogrel could control the platelet aggregation of severe carotid stenosis after surgery to prevent the thrombogenesis and decrease the restriction incidence,while control the inflammation factor expression to prevent the atherosclerosis.

Influence of clopidogrel on platelet function and inflammation factor in treatment of severe carotid artery stenosis after stent-assisted angioplasty / 药物评价研究

Objective To investigate the effect of clopidogrel on platelet function and inflammation factor in treatment of severe carotid artery stenosis after stent-assisted angioplasty.Methods Patients (120 cases) with severe carotid artery stenosis after stent-assisted angioplasty were chosen and divided into two groups,the control group were given atorvastatin combined with aspirin,and the observation group were given atorvastatin combined with chlorine.The serum coagulants DD level,FIB level,inflammation factor P-chosen element level and restenosis event incidence of two groups were observed.Results D-double polymer of two groups had no significant difference;After surgery,the D-double polymer and FIB level of two groups were all higher (P ＜ 0.05).After surgery for 24 h,the D-double polymer and FIB level of observation group were higher,after 3 months of surgery,the D-double polymer and FIB level had no significant differences compared with before surgery,which were all in normal level.After 24 h,1 month,3 months of surgery,the D-double polymer and FIB level of observation group were all lower than control group (P ＜ 0.05).Before treatment,the P-chosen selectin of two groups had no significant differences,which were all decreased after surgery,and the observation group was lower than control group (P ＜ 0.05);The restenosis event of observation group was lower than control group (P ＜ 0.05).Conclusion Clopidogrel could control the platelet aggregation of severe carotid stenosis after surgery to prevent the thrombogenesis and decrease the restriction incidence,while control the inflammation factor expression to prevent the atherosclerosis.

A Case of Acquired Factor V Deficiency after Percutaneous Coronary Intervention / 대한내과학회지

Acquired factor V deficiency is extremely rare. Here we report the case of an 88-year-old female patient who presented with hematochezia 1 month after undergoing percutaneous coronary intervention. Her laboratory results showed an extremely prolonged prothrombin time and an activated partial thromboplastin time, but neither improved after fresh frozen plasma transfusion. She was finally diagnosed with acquired factor V deficiency and successfully treated with an immunosuppressant.

The Relation between Coagulation Profile Test and Outcome in Survivors who were Treated with Therapeutic Hypothermia after Cardiopulmonary Resuscitation

PURPOSE: The purpose of this study is to clarify the clinical significance of coagulation factor as a prognostic tool in patients with cardiac arrest treated with therapeutic hypothermia (TH). METHODS: We designed a retrospective case review study in one university hospital. All adult patients who suffered cardiac arrest from December 2011 to February 2014 were considered for inclusion in the study. Patients who did not undergo TH were excluded from the analysis. Patients with any hematologic disorder were also excluded. Patients were divided into two groups, the good outcome group and the poor outcome group depending on the final cerebral performance category (CPC). Serum D-dimer, FDP, PT, aPTT, anti-thrombin III, fibrinogen, Troponin T, CK-MB, Troponin-I, DIC score, NSE, and S-100 were taken within one hour after ROSC. Logistic regression was used for multivariable analysis. RESULTS: A total of 92 patients were included; 22 in the good outcome group, 70 in the poor outcome group. The median serum PT, aPTT, FDP, fibrinogen, and D-dimer levels were grossly elevated in the poor outcome group. Only serum PT, D-dimer level showed significant association with poor outcome (PT: OR=1.577; 95% CI=1.08-17.49, D-dimer: OR=1.577; 95% CI=1.06-2.33). The area under the receiver operating characteristic (AUC) of PT, D-dimer, and S-100 for prediction of poor outcome was 0.822 (95% CI=0.72-0.89), 0.68 (95% CI=0.57-0.77), and 0.811 (95% CI=0.70-0.89), respectively. Other factors were not associated with prognosis. CONCLUSION: Increased PT and D-dimer levels are significantly associated with poor outcome. PT and D-dimer values have potential for use as new prognostic predictors along with the current prognostic factor, S-100 protein.

Arterial Pseudoaneurysm in Neonates with Hemophilia: Successful Treatment with Noninvasive Clotting Factor Replacement and Ultrasound-guided Compression

Vascular cannulation is an invasive procedure that carries the risk of complications such as pseudoaneurysms. Hemophilia, the most common severe bleeding disorder of inheritance, increases the risk of such complications through underlying hypocoagulability. Although surgical ligation has been considered the gold standard treatment, less invasive options are currently available. Here we present 2 hemophiliac neonates for whom clotting factor replacement and ultrasound (US)-guided compression were successfully used. A 3-week-old male infant and a 4-week-old male infant presented with masses in the left antecubital area and the radial aspects of both wrists, respectively, after arterial punctures. The US confirmed the presence of pseudoaneurysms located at the left brachial artery and right radial artery. US-guided compressions with clotting factor administration initially attempted while confirming a thrombus inside the pseudoaneurysm sac indicated successful management. Arterial cannulation and other procedures in hemophiliac neonates must be attempted with caution because pseudoaneurysms or uncontrolled bleeding may occur. If laboratory analyses or invasive procedures are needed for neonates with a bleeding tendency or a suspected hemophiliac disorder, arterial or venous cannulation requires more caution or should be avoided if possible. This case report suggests that US-guided compression and clotting factor administration are suitable modalities for the treatment of small pseudoaneurysms in hemophilia patients.

Antibiotic-Induced Acquired Factor V Inhibitor / 대한내과학회지

Acquired factor V inhibitor is a rare condition with a variety of clinical manifestations that range from no bleeding symptoms to life-threatening hemorrhage or thromboembolic events. Treatment is determined by the clinical course and focuses on controlling the hemorrhagic event and decreasing the antibody titer if bleeding symptoms are present. We report herein a case involving a 70-year-old man who developed acquired factor V inhibitor after antibiotic administration (11-day course of ceftriaxone and successive 5-day course of piperacillin-tazobactam) for pneumonia. His condition was characterized by elevated prothrombin and activated partial thromboplastin times without bleeding events. Coagulation factor assays revealed undetectable factor V activity and a factor V inhibitor level of 3.29 Bethesda units. After cessation of the antibiotics, both the prothrombin and activated partial thromboplastin times gradually normalized.

A Case of Acquired Factor V Deficiency Treated with Corticosteroids and Cyclophosphamide / 대한내과학회지

Acquired factor V deficiency is a rare bleeding disorder, the severity of which ranges from mild to fatal. There are various suggested treatments, including transfusion of fresh frozen plasma (FFP) or platelets, plasmapheresis and immunosuppressive therapy. We encountered a case of idiopathic acquired factor V deficiency with fatal retroperitoneal bleeding treated with steroid and cyclophosphamide.

A Case of Acquired Factor V Deficiency Treated with Corticosteroids and Cyclophosphamide / 대한내과학회지

Acquired factor V deficiency is a rare bleeding disorder, the severity of which ranges from mild to fatal. There are various suggested treatments, including transfusion of fresh frozen plasma (FFP) or platelets, plasmapheresis and immunosuppressive therapy. We encountered a case of idiopathic acquired factor V deficiency with fatal retroperitoneal bleeding treated with steroid and cyclophosphamide.

Research about the relationship of tissue factor, tissue factor pathway inhibitor-1, 2 with cancer metastases and thrombosis / 肿瘤研究与临床

Objective To evaluate the effect of tissue factor (TF), tissue factor pathway inhibitor-1,2 (TFPI-1,2) on cancer metastases and thrombosis complicated with cancer. Methods Blood samples from 292 cancer patients were collected and were divided into different teams according to cancer types,complicated with or without thrombosis; TF, TFPI-1, TFPI-2, plasma concentrations were measured by ELISA;Tissue expression of TF, TFPI-1, TFPI-2 were observed by immunohistochemical method. Results Plasma concentrations of TF and TFPI-1 in all kinds of cancers were higher than the control and lung cancer was the highest; TFPI-2 plasma concentrations had no statistics differences among all these teams. Tissue expression of TF of all kinds of cancer were higher than the adjacent tissues, lung cancer was higher than the other types of cancer. There were no statistics differences for TFPI-1 and TFPI-2. Both TF and TFPI-1 plasma concentrations of cancer with-or without-thrombosis were higher than control. TF was even higher in cancer with thrombosis team, TFPI-1 had no statistic difference between these two teams. TFPI-2 concentrations had no differences among all these teams. Conclusion Many kinds of tumor have higher expression of TF, it is expressed with different intensity according to different types of cancer. TFPI-1 has no clear effect in cancer growing and metastases. Unbalance of TF and TFPI-1 in plasma may relate to high coagulation state of cancer and may accelerate the thrombosis formation in cancer.

A Case of Acquired Factor V Inhibitor

Acquired inhibitor of coagulation factor V is a rare clinical condition and may cause significant morbidity and mortality. We report here the first Korean case of acquired isolated factor V inhibitor developed in a 73-year-old male patient after surgery for pancreatic head carcinoma. At post-operation day 2, intra-abdominal bleeding was recognized that was associated with a prolonged prothrombin time and activated partial thromboplastin time. The prolongation of both conditions was not corrected by a mixing test and factor V activity was reported to be 2%. Quantified titers of inhibitors were increased from 3.5 Bethesda unit to 8.4 Bethesda unit during follow-up analysis. In spite of the treatment with steroids and intravenous immunoglobulins, the case ended fatally. When acquired bleeding tendency with prolonged coagulation screening test is observed, evaluation of inhibitors of coagulation factors may be essential for the diagnosis and following appropriate management of the condition.

Present Status of Hereditary Thrombophilia / 中国普外基础与临床杂志

Objective To summarize the advancement of hereditary thrombophilia.Methods Relevant literatures about hereditary thrombophilia published recently domestic and abroad were reviewed and analyzed.Results The hereditary risk factors of venous thromboembolism were different among different races.In western population,the main risk factors were activated protein C resistance (APC-R) and mutation of factor V Leiden,methylene tetrahydrofolate reductase polymorphism (C677T) and prothrombin G20210A.While in Chinese population,the disorder of protein C system and hyperhomocysteinemia were the major genetic risk factor.The existence of multiple genetic risk factors increased the incidence of primary and recurrent venous thromboembolism.Conclusion Further study on the relations between the hereditary risk factors and thrombophilia will be very important for prediction and prevention of the venous thromboembolism.

RFLP Analysis of a Gene for Blood Coagulation Factor IX in Korean / 대한산부인과학회잡지

OBJECTIVE: The purpose of this study was to investigate the methods for analysis of restriction fragment length polymorphisms of hemophilia B (coagulation factorIX) gene in Korean population. METHODS: Genomic DNAs were extracted from 40 Korean females. In order to amplify genomic DNAs at the region of the polymorphic sites, two sets of primers (Hha I and Dde I) were synthesized. The primers were named as FIX1, FIX2 for Hha I, and Dde I 59, Dde I 39 for Dde I, respectively. Hha I primers annealed 3'-flanking region of the FactorIX gene and amplified 230 bp long fragment. The PCR fragment (230 bp) treated with Hha I endonuclease produced two fragments (150 bp and 80 bp), when the polymorphic site existed. Dde I primers annealed the region of the first intron of Factor IX gene and amplified 319 bp long fragments. People cases with Dde I polymorphic site are supposed to produce 369 bp long fragment. Results: It has been found that seven (14 X chromosomes) out of forty individuals showed Hha I polymorphism. However, none of the experimental People cases showed the Dde I polymorphism. CONCLUSIONS: By the analysis of 80 chromosomes, the PICs calculated from allele frequency of Hha I-RFLP (0.175/0.825) and that of Dde I-RFLP (0.0/1.0) were 0.289=[1-(0.1752+0.8252)] and 0=[1-(02+12)], respectively. From these results, it can be postulated that Hha I and Dde I polymorphisms of the Factor IX gene in Korean exhibited different patterns from those of Caucasian.

Experiment Research of Alteration of Blood Lipids,Glucose and Blood Goagulation Factors in Hyperlipoidemia / 中国医师杂志

Objective To study the changes and correlations of the blood lipids, glucose and blood coagulation factors in the animal models and patients with lipodystrophia. Methods The models of hyperlipoidemia were set up in 30 rabbits, and 40 cases of the hyperlipoidemia and 40 cases of the healthy subjects randomly were enrolled in this study. Their blood lipids, glucose and coagulation factors were detected. Results The serum levels of TC,TG,LDL-C and Glu in the rabbit models and patients with hyperlipoidemia notably increased compared with controls(P0 05). HDL-C level increased in the rabbit models(P0 05). Conclusions The change of the blood lipids level in the rabbit models was different from that of the patients with hyperlipoidemia. But both may company the abnormality of carbohydrate metabolism, and hyperlipoidemia may affect the endogenous blood coagulation system to cause the blood to present the high coagulation.